|
Systemic Scleroderma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also examined the effects of COA-Cl on CTGF expression in a mouse SSc model of angiotensin II (Ang II)-induced skin fibrosis.
|
30954335 |
2019 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with rMFG-E8 significantly inhibited latent TGFβ-induced expression of type I collagen, α-smooth muscle actin, and CCN2 in SSc fibroblasts (n = 3-8), which suggested that MFG-E8 inhibited activation of latent TGFβ as well as TGFβ signaling via binding to αv integrin.
|
30175895 |
2019 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Skin gene expression of biomarkers associated with macrophages (CD14, IL13RA1) and transforming growth factor β activation (SERPINE1, CTGF, OSMR) are prognostic for progressive skin disease in patients with dcSSc.
|
29858547 |
2018 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our aim was to examine the therapeutic potential of CTGF blockade in a preclinical model of SSc using two approaches: smooth muscle cell fibroblast-specific deletion of CTGF (CTGF knockout (KO)) or a human anti-CTGF monoclonal antibody, FG-3019.
|
28610597 |
2017 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PDGF receptor α mRNA correlated with CCN2 and other fibrotic markers in the skin of SSc patients.
|
28433542 |
2017 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, the role of cytokine (interleukin-1β, interleukin-6) and connective tissue growth factor (CTGF) production, and extracellular signal-regulated kinases (ERK) activation in mediating P2X7R-dependent pro-fibrotic effects in SSc fibroblasts was evaluated.
|
28955239 |
2017 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since IRF5, STAT4, and IRAK1 are important regulatory factors in the control of innate immune responses and CTGF is involved in the synthesis of extracellular matrix, these results suggest a role of the innate immunity and matrix compounds in the pathogenesis of PF in SSc.
|
28434122 |
2017 |
|
Systemic Scleroderma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that Repsox has the most potent inhibitory effects on TGF-β-induced expression of CTGF and collagen of cultured normal dermal fibroblasts in vitro and their constitutive overexpression of scleroderma fibroblast in vitro.
|
28418584 |
2017 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
VSMC differentiation towards both, contractile and synthetic VSMC phenotypes in response to CTGF and b-FGF was disturbed in SSc-MSCs.
|
27054717 |
2016 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression levels of other TGF-β-regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively), and a 2-gene, longitudinal pharmacodynamic biomarker of SSc skin disease decreased after fresolimumab treatment (P = 0.0067).
|
26098215 |
2015 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.
|
24706986 |
2014 |
|
Systemic Scleroderma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to validate the evidence for the CTGF -945C/G polymorphism and systemic sclerosis risk.
|
22906474 |
2012 |
|
Systemic Scleroderma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Connective tissue growth factor (CTGF) has been implicated in the cardiac and kidney complications of type 2 diabetes, and the CTGF -945 G/C polymorphism is associated with susceptibility to systemic sclerosis, a disease characterised by tissue fibrosis.
|
22533709 |
2012 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our investigations revealed that roscovitine coordinately inhibited the expression of collagen, fibronectin, and connective tissue growth factor (CTGF) in normal and SSc fibroblasts.
|
23185265 |
2012 |
|
Systemic Scleroderma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Connective tissue growth factor (CCN2) gene expression was significantly reduced and matrix metalloproteinase 1 (MMP1) levels were enhanced after ciprofloxacin treatment to a similar extent in healthy and SSc fibroblasts.
|
23041765 |
2012 |
|
Systemic Scleroderma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, this study has revealed an important role of cav-1 in mediating TGFβ/Smad1 signaling and CCN2 gene expression in healthy and SSc dermal fibroblasts.
|
22277251 |
2012 |
|
Systemic Scleroderma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, IL-17A, not IL-17F, reduced the protein expression of α1(I) collagen and connective tissue growth factor. miR-129-5p, one of the downregulated microRNAs in SSc fibroblasts, increased due to IL-17A and mediated the α1(I) collagen reduction.
|
22403442 |
2012 |
|
Systemic Scleroderma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We further found that the expression of TGF-β1, CTGF and type I and type III collagen mRNA was inhibited by MK886 in scleroderma fibroblasts.
|
21352343 |
2011 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis.
|
20653770 |
2010 |
|
Systemic Scleroderma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We assessed the possible association between 7 single-nucleotide polymorphisms (SNP) in the CTGF gene and scleroderma in a French population (registration number 2006/0182).
|
20032097 |
2010 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings show CTGF to be a rational target for therapy in fibrotic diseases such as SSc.
|
19565505 |
2009 |
|
Systemic Scleroderma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CTGF has been linked to transforming growth factor-beta (TGF-beta) pathways in fibroproliferative diseases and specific polymorphisms within the CTGF gene may predispose for fibrosis in systemic sclerosis.
|
19243500 |
2009 |
|
Systemic Scleroderma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results do not confirm previous findings and suggest that the CTGF -945 promoter polymorphism does not play a major role in SSc susceptibility or clinical phenotype.
|
19054816 |
2009 |
|
Systemic Scleroderma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study confirms the association between an SNP in the CTGF gene and susceptibility to SSc, especially in the presence of diffuse cutaneous SSc, interstitial lung disease and anti-topoisomerase I antibody.
|
19054818 |
2009 |
|
Systemic Scleroderma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Scleroderma lung fibroblasts and normal lung fibroblasts treated with CTGF demonstrated increased rate of migration in a wound healing assay.
|
18676875 |
2008 |